Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression.

Front Oncol · 2026 · PMC13278892 · PMID 42326340

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Atezolizumab combined with Entinostat and chemotherapy (Atezo-Entino-chemo) showed a trend toward improved OS (HR = 0.49, 95% CI: 0.22-1.12) and ORR (OR = 5.14, 95% CI: 0.70-37.94).

also in 53,322 other papers

an increasing trendno p-value reported

In first-line treatment of mTNBC, ICIs combined with chemotherapy significantly improve OS and PFS compared to chemotherapy alone, with an increasing trend in ORR, although it did not reach statistical significance.

also in 63,971 other papers

did not reach statistical significanceno p-value reported

The results showed that although ICIs combined with chemotherapy improved ORR compared to chemotherapy alone (OR = 1.56, 95% CI: 0.88-2.75), the difference did not reach statistical significance ( Figure 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.